Orchid Pharmaceuticals - Orchid Chemicals,pharmaceutical,cephalosporin,bulk drug,formulations,nutraceutical,orchid pharmaceuticals,research & development,pharmaceutical company,alendronate sodium tablets,new drug discovery,cefixime tablets,nimesulide dispersible tablets,amoldipine tablets,new drug delivery systems,quality manufacturing facilities,amlodipine atenolol tablets,sildenafil citrate tablets,ISO 9002,ISO 14001,investors, annual report,careers pharmaceutical,careers research & development,novel drug delivery systems,cefpodoxime proxetil tablets,quality control pharmaceutical formulations,pharmaceutical research,contract manufacture,bulk drug contract manufacture,formulations contract manufacture,contract research,state-of -the art R&D,lisinopril tablets,calcitriol soft gel capsules

The increase in the capital is on account of the allotment of 1,06,53,192 equity shares of Rs.10/- each with premium to the Foreign Investors belonging to Schroder Ventures Group on private placement basis in December 1999.
A fire incident occurred in January 2000 in one of the production blocks at Alathur Bulk Drug Plant. The Company has completed revamping of the said block and normalcy was restored during the last quarter.
The Company has acquired the Bulk Drug Plant of M/s. Ajanta Pharma Ltd located at Aurangabad and commenced commercial production in March 2000.
On April 14, 2000, the Board of Directors have declared an Interim Dividend of 40 % on the paid-up equity capital of Rs. 2799.92 lakhs for the financial year ended 31st March, 2000.
The Board at its meeting held on May 11, 2000, has taken on record the above audited financial results for the year ended March 31, 2000.


Orchid Chemicals & Pharmaceuticals Ltd
Audited Financial Results for the year ended March 31, 2000
Rs. Lakhs
Sl No	Particulars	Year Ended 31.03.2000 (Audited)	Year Ended 31.03.1999 (Audited)
1	Sales and Operating Income	35,954.80	33,435.04
2	Other Income	377.34	149.60
3	Total Expenditure	25,648.13	25,160.52
	a) Decrease/(Increase) in Stock in trade	(1,197.23)	(1,197.96)
	b) Consumption of raw materials	18,023.61	20,597.71
	c) Staff Cost	1,748.08	1,024.29
	d) Other Expenditure	7,073.67	4,736.48
4	Interest and Finance Charges	4,191.95	3,191.96
5	Gross Profit after Interest but before Depreciation and Taxation (!+2+3-4)	6,492.06	5,232.16
6	Depreciation	2,633.05	1,678.09
7	Provision for Taxation	--	0.35
8	Net Profit (5-6-7)	3,859.01	3,553.72
9	Paid- up Equity Share Capital (Face value of Rs. 10 each)	2,799.92	1,734.60
10	Reserves excluding Revaluation Reserves	34221.08	15,246.92
11	Earning Per Share (Rs.) (Annualised)	18.67	20.49
12	Book Value (Rs.)	132.22	97.90

The increase in the capital is on account of the allotment of 1,06,53,192 equity shares of Rs.10/- each with premium to the Foreign Investors belonging to Schroder Ventures Group on private placement basis in December 1999. A fire incident occurred in January 2000 in one of the production blocks at Alathur Bulk Drug Plant. The Company has completed revamping of the said block and normalcy was restored during the last quarter. The Company has acquired the Bulk Drug Plant of M/s. Ajanta Pharma Ltd located at Aurangabad and commenced commercial production in March 2000. On April 14, 2000, the Board of Directors have declared an Interim Dividend of 40 % on the paid-up equity capital of Rs. 2799.92 lakhs for the financial year ended 31st March, 2000. The Board at its meeting held on May 11, 2000, has taken on record the above audited financial results for the year ended March 31, 2000.